keyword
MENU ▼
Read by QxMD icon Read
search

dmards RA failure biologicals

keyword
https://www.readbyqxmd.com/read/28429118/-how-frequent-are-poor-prognostic-markers-in-rheumatoid-arthritis-an-estimate-based-on-three-epidemiologic-cohorts
#1
K Albrecht, A Richter, Y Meissner, D Huscher, L Baganz, K Thiele, M Schneider, A Strangfeld, A Zink
BACKGROUND: Unfavorable prognostic factors-high disease activity, early erosions, and autoantibodies-should be considered when making treatment decisions in rheumatoid arthritis (RA). There are little data on the frequency of individual poor prognostic factors among RA patients in daily care. METHODS: Disease activity (Disease Activity Score, DAS28), erosions, antibodies against citrullinated peptides or rheumatoid factor (ACPA/RF+), previous treatment failure, inflammation markers, and functional disability (FFbH < 70) were defined as prognostic factors...
April 20, 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/28412710/triple-oral-therapy-versus-antitumor-necrosis-factor-plus-methotrexate-mtx-in-patients-with-rheumatoid-arthritis-and-inadequate-response-to-mtx-a-systematic-literature-review
#2
Julia Mary, Michel De Bandt, Cédric Lukas, Jacques Morel, Bernard Combe
OBJECTIVE: For patients with rheumatoid arthritis (RA) who have an inadequate response to methotrexate (MTX), the relative effectiveness of the combination of conventional disease-modifying antirheumatic drugs (DMARD) compared with the combination of tumor necrosis factor (TNF) inhibitors and MTX, as second-line therapy, is uncertain. The aim of this study was to compare the efficacy and tolerance of triple oral DMARD therapy versus anti-TNF agents associated with MTX in patients with RA after MTX failure...
April 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28264816/eular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic-and-biological-disease-modifying-antirheumatic-drugs-2016-update
#3
Josef S Smolen, Robert Landewé, Johannes Bijlsma, Gerd Burmester, Katerina Chatzidionysiou, Maxime Dougados, Jackie Nam, Sofia Ramiro, Marieke Voshaar, Ronald van Vollenhoven, Daniel Aletaha, Martin Aringer, Maarten Boers, Chris D Buckley, Frank Buttgereit, Vivian Bykerk, Mario Cardiel, Bernard Combe, Maurizio Cutolo, Yvonne van Eijk-Hustings, Paul Emery, Axel Finckh, Cem Gabay, Juan Gomez-Reino, Laure Gossec, Jacques-Eric Gottenberg, Johanna M W Hazes, Tom Huizinga, Meghna Jani, Dmitry Karateev, Marios Kouloumas, Tore Kvien, Zhanguo Li, Xavier Mariette, Iain McInnes, Eduardo Mysler, Peter Nash, Karel Pavelka, Gyula Poór, Christophe Richez, Piet van Riel, Andrea Rubbert-Roth, Kenneth Saag, Jose da Silva, Tanja Stamm, Tsutomu Takeuchi, René Westhovens, Maarten de Wit, Désirée van der Heijde
Recent insights in rheumatoid arthritis (RA) necessitated updating the European League Against Rheumatism (EULAR) RA management recommendations. A large international Task Force based decisions on evidence from 3 systematic literature reviews, developing 4 overarching principles and 12 recommendations (vs 3 and 14, respectively, in 2013). The recommendations address conventional synthetic (cs) disease-modifying antirheumatic drugs (DMARDs) (methotrexate (MTX), leflunomide, sulfasalazine); glucocorticoids (GC); biological (b) DMARDs (tumour necrosis factor (TNF)-inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, tocilizumab, clazakizumab, sarilumab and sirukumab and biosimilar (bs) DMARDs) and targeted synthetic (ts) DMARDs (Janus kinase (Jak) inhibitors tofacitinib, baricitinib)...
March 6, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28151971/eq-5d-utility-response-and-drug-survival-in-rheumatoid-arthritis-patients-on-biologic-monotherapy-a-prospective-observational-study-of-patients-registered-in-the-south-swedish-ssatg-registry
#4
Tanja Schjødt Jørgensen, Carl Turesson, Meliha Kapetanovic, Martin Englund, Aleksandra Turkiewicz, Robin Christensen, Henning Bliddal, Pierre Geborek, Lars Erik Kristensen
OBJECTIVES: Biologic agents have dramatically changed treatment of rheumatoid arthritis (RA). To date only scarce head-to-head data exist especially when the biological therapies are given as monotherapy without concomitant disease modifying drugs (DMARDs). Thus the objective of the current study is to evaluate treatment response of all available biological therapies with special focus on utility (EQ-5D-3L) and drug survival of biologic DMARDs (bDMARDs) prescribed as monotherapy in RA patients in southern Sweden...
2017: PloS One
https://www.readbyqxmd.com/read/28132102/comparative-effectiveness-of-treatment-options-after-conventional-dmards-failure-in-rheumatoid-arthritis
#5
Yoon-Kyoung Sung, Soo-Kyung Cho, Dam Kim, Chan-Bum Choi, Soyoung Won, So-Young Bang, Hoon-Suk Cha, Jung-Yoon Choe, Won Tae Chung, Seung-Jae Hong, Jae-Bum Jun, Hyoun Ah Kim, Jinseok Kim, Seong-Kyu Kim, Tae-Hwan Kim, Hye-Soon Lee, Jaejoon Lee, Jisoo Lee, Shin-Seok Lee, Sung Won Lee, Yeon-Ah Lee, Seong-Su Nah, Chang-Hee Suh, Dae-Hyun Yoo, Bo Young Yoon, Sang Cheol Bae
OBJECTIVE: To compare the clinical effectiveness of two treatment strategies for active rheumatoid arthritis (RA) refractory to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs): starting TNF inhibitors (TNFIs) or changing csDMARDs. METHODS: We used two nationwide Korean RA registries for patient selection. TNFI users were selected from the BIOPSY, which is an inception cohort of RA patients starting biologic DMARDs. As a control group, we selected RA patients with moderate or high disease activity from the KORONA database whose treatment was changed to other csDMARDs...
January 28, 2017: Rheumatology International
https://www.readbyqxmd.com/read/28079512/long-term-treatment-response-in-rheumatoid-arthritis-patients-starting-adalimumab-or-etanercept-with-or-without-concomitant-methotrexate
#6
Merel J l'Ami, Eva L Kneepkens, Michael T Nurmohamed, Charlotte L M Krieckaert, Ingrid M Visman, Gert-Jan Wolbink
OBJECTIVES: To observe long-term clinical response and drug survival in a prospective two-year cohort study in rheumatoid arthritis (RA) patients starting adalimumab or etanercept treatment, with or without methotrexate (MTX), after failure of conventional DMARD therapy, including MTX. METHODS: Disease activity score of 28 joints (DAS28) and Health Assessment Questionnaire (HAQ) were collected of 873 consecutive RA patients, treated with adalimumab or etanercept, prospectively at baseline, 4, 16, 28, 40, 52, 78 and 104 weeks of biological therapy...
January 5, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/27855242/biologic-or-tofacitinib-monotherapy-for-rheumatoid-arthritis-in-people-with-traditional-disease-modifying-anti-rheumatic-drug-dmard-failure-a-cochrane-systematic-review-and-network-meta-analysis-nma
#7
REVIEW
Jasvinder A Singh, Alomgir Hossain, Elizabeth Tanjong Ghogomu, Amy S Mudano, Peter Tugwell, George A Wells
BACKGROUND: We performed a systematic review, a standard meta-analysis and network meta-analysis (NMA), which updates the 2009 Cochrane Overview, 'Biologics for rheumatoid arthritis (RA)'. This review is focused on biologic monotherapy in people with RA in whom treatment with traditional disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) had failed (MTX/other DMARD-experienced). OBJECTIVES: To assess the benefits and harms of biologic monotherapy (includes anti-tumor necrosis factor (TNF) (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab) or non-TNF (abatacept, anakinra, rituximab, tocilizumab)) or tofacitinib monotherapy (oral small molecule) versus comparator (placebo or MTX/other DMARDs) in adults with RA who were MTX/other DMARD-experienced...
November 17, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27722215/jak-inhibitors-a-broadening-approach-in-rheumatoid-arthritis
#8
S Lam
Pfizer's Xeljanz (tofacitinib citrate) was the first Janus kinase (JAK) inhibitor to reach the market for rheumatoid arthritis (RA) following its U.S. approval in November 2012, and it has since gained approval in more than 45 countries as a second-line therapy for RA after failure of disease-modifying antirheumatic drugs (DMARDs). This emerging category has heralded an attractive new class of oral treatment options in RA, with a notable opportunity in patients who stop responding to DMARDs, but they are facing a challenging market...
August 2016: Drugs of Today
https://www.readbyqxmd.com/read/27721905/combination-therapy-with-biologic-agents-in-rheumatic-diseases-current-and-future-prospects
#9
REVIEW
Kentaro Inui, Tatsuya Koike
Strategies in rheumatoid arthritis (RA) based on 'treat to target' aim to control disease activity, minimize structural damage, and promote longer life. Several disease-modifying antirheumatic drugs (DMARDs) have been shown to be effective including biological DMARDs (bDMARDs). Treatment guidelines and recommendations for RA have also been published. According to those guidelines, conventional synthetic DMARDs (csDMARDs), as monotherapy or combination therapy, should be used in DMARD-naïve patients, irrespective of the addition of glucocorticoids (GCs)...
October 2016: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/27518855/-the-first-biologic-for-rheumatoid-arthritis-factors-influencing-the-therapeutic-decision
#10
D Pattloch, A Richter, B Manger, R Dockhorn, L Meier, H-P Tony, A Zink, A Strangfeld
BACKGROUND AND AIMS: Biologics (disease modifying antirheumatic drugs, bDMARD) have been in use in Germany for the treatment of rheumatoid arthritis (RA) since 2001, usually after failure of at least one conventional synthetic (cs)DMARD. We analyzed temporal changes in factors that influence the decision for either a first bDMARD or a further csDMARD. MATERIAL AND METHODS: We analyzed data from 9513 bDMARD-naive RA patients in the German biologics register RABBIT who switched to a new therapy...
August 12, 2016: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/27443588/cardiovascular-safety-findings-in-patients-with-rheumatoid-arthritis-treated-with-tofacitinib-an-oral-janus-kinase-inhibitor
#11
Christina Charles-Schoeman, Pierre Wicker, Miguel A Gonzalez-Gay, Mary Boy, Andrea Zuckerman, Koshika Soma, Jamie Geier, Kenneth Kwok, Richard Riese
OBJECTIVES: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). The implications of treatment with tofacitinib on cardiovascular (CV) risk in RA are unknown. Therefore, CV adverse events (AEs), and blood pressure and lipid level changes, in tofacitinib-treated patients with RA were evaluated. METHODS: Data were pooled from six Phase (P)3 studies (24 months) and two open-label long-term extension (LTE) studies (60 months) of tofacitinib in patients with RA and inadequate response to DMARDs...
December 2016: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/27030256/serum-calprotectin-levels-as-a-marker-of-arthritis-an-italian-experience
#12
Valentina Grossi, Maria Infantino, Mariangela Manfredi, Francesca Meacci, Emanuele Bellio, Valerio Bellio, Francesca Li Gobbi, Simone Ugolini, Stefano Catani, Piercarlo Sarzi-Puttini, Fabiola Atzeni, Maurizio Benucci
BACKGROUND: The identification and validation of soluble markers provide significant opportunities for managing patients with rheumatic diseases, and calprotectin may be an alternative laboratory biomarker of inflammatory rheumatoid arthritis (RA) and psoriatic arthritis (PsA) even though its levels may vary considerably. The aim of this study was to propose a calprotectin cut-off value that would be useful for distinguishing patients with inflammatory arthritis or non-inflammatory arthritis (NIA) in clinical practice...
March 31, 2016: Current Rheumatology Reviews
https://www.readbyqxmd.com/read/26545940/2015-american-college-of-rheumatology-guideline-for-the-treatment-of-rheumatoid-arthritis
#13
REVIEW
Jasvinder A Singh, Kenneth G Saag, S Louis Bridges, Elie A Akl, Raveendhara R Bannuru, Matthew C Sullivan, Elizaveta Vaysbrot, Christine McNaughton, Mikala Osani, Robert H Shmerling, Jeffrey R Curtis, Daniel E Furst, Deborah Parks, Arthur Kavanaugh, James O'Dell, Charles King, Amye Leong, Eric L Matteson, John T Schousboe, Barbara Drevlow, Seth Ginsberg, James Grober, E William St Clair, Elizabeth Tindall, Amy S Miller, Timothy McAlindon
OBJECTIVE: To develop a new evidence-based, pharmacologic treatment guideline for rheumatoid arthritis (RA). METHODS: We conducted systematic reviews to synthesize the evidence for the benefits and harms of various treatment options. We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology to rate the quality of evidence. We employed a group consensus process to grade the strength of recommendations (either strong or conditional)...
January 2016: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/26545825/2015-american-college-of-rheumatology-guideline-for-the-treatment-of-rheumatoid-arthritis
#14
REVIEW
Jasvinder A Singh, Kenneth G Saag, S Louis Bridges, Elie A Akl, Raveendhara R Bannuru, Matthew C Sullivan, Elizaveta Vaysbrot, Christine McNaughton, Mikala Osani, Robert H Shmerling, Jeffrey R Curtis, Daniel E Furst, Deborah Parks, Arthur Kavanaugh, James O'Dell, Charles King, Amye Leong, Eric L Matteson, John T Schousboe, Barbara Drevlow, Seth Ginsberg, James Grober, E William St Clair, Elizabeth Tindall, Amy S Miller, Timothy McAlindon
OBJECTIVE: To develop a new evidence-based, pharmacologic treatment guideline for rheumatoid arthritis (RA). METHODS: We conducted systematic reviews to synthesize the evidence for the benefits and harms of various treatment options. We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology to rate the quality of evidence. We employed a group consensus process to grade the strength of recommendations (either strong or conditional)...
January 2016: Arthritis Care & Research
https://www.readbyqxmd.com/read/26456224/update-on-the-2012-brazilian-society-of-rheumatology-guidelines-for-the-treatment-of-rheumatoid-arthritis-position-on-the-use-of-tofacitinib
#15
Licia Maria Henrique da Mota, Bóris Afonso Cruz, Cleandro Pires de Albuquerque, Deborah Pereira Gonçalves, Ieda Maria Magalhães Laurindo, Ivanio Alves Pereira, Jozélio Freire de Carvalho, Geraldo da Rocha Castelar Pinheiro, Manoel Barros Bertolo, Maria Raquel da Costa Pinto, Paulo Louzada-Junior, Ricardo Machado Xavier, Rina Dalva Neubarth Giorgi, Rodrigo Aires Corrêa Lima
In 2014, tofacitinib, a target-specific, synthetic disease modifying anti rheumatic drug (DMARD) and a selective inhibitor of Janus kinase (JAK) was approved for use in Brazil. This position paper aims to update the recommendations of the Brazilian Society of Rheumatology (SBR) on the treatment of rheumatoid arthritis (RA) in Brazil, specifically regarding the use of target-specific synthetic DMARDs. The method of this recommendation consisted of a literature review of scientific papers held on the Medline database...
November 2015: Revista Brasileira de Reumatologia
https://www.readbyqxmd.com/read/26373561/increased-prevalence-of-diastolic-heart-failure-in-patients-with-rheumatoid-arthritis-correlates-with-active-disease-but-not-with-treatment-type
#16
COMPARATIVE STUDY
Thomas Schau, Michael Gottwald, Olga Arbach, Martin Seifert, Maren Schöpp, Michael Neuß, Christian Butter, Michael Zänker
OBJECTIVE: Although heart failure (HF) is a major cause of premature mortality, there is little information regarding its prevalence and associated risk factors in patients with rheumatoid arthritis (RA). In this study, we evaluated the prevalence of HF in a community-based RA cohort. Further, we investigated the effect of RA activity and present treatment on HF rate and cardiac structure. METHODS: A diagnostic workup for HF according to the European Society of Cardiology recommendations was performed in 157 patients with RA fulfilling the American College of Rheumatology/European League Against Rheumatism criteria (68% women, age 61 ± 13 yrs) from our outpatient clinic and in 77 age- and sex-matched controls...
November 2015: Journal of Rheumatology
https://www.readbyqxmd.com/read/26350484/low-rates-of-biologic-free-clinical-disease-activity-index-remission-maintenance-after-biologic-disease-modifying-anti-rheumatic-drug-discontinuation-while-in-remission-in-a-japanese-multicentre-rheumatoid-arthritis-registry
#17
MULTICENTER STUDY
Kazuki Yoshida, Mitsumasa Kishimoto, Helga Radner, Kazuo Matsui, Masato Okada, Yukihiko Saeki, Daniel H Solomon, Shigeto Tohma
OBJECTIVE: To examine in detail the outcomes of biologic DMARD (bDMARD) discontinuation while in remission occurring in daily clinical practice settings. We examined a multicentre longitudinal registry of RA patients. METHODS: We utilized data from the NinJa multicenter registry in Japan. Patients who used bDMARDs and had one or more successive visits in remission (defined by the clinical disease activity index (CDAI) ≤2.8) before discontinuation were included...
February 2016: Rheumatology
https://www.readbyqxmd.com/read/26001633/health-related-quality-of-life-in-patients-with-long-standing-rheumatoid-arthritis-in-the-era-of-biologics-data-from-the-german-biologics-register-rabbit
#18
COMPARATIVE STUDY
Kerstin Gerhold, Adrian Richter, Matthias Schneider, Hans-Joachim Bergerhausen, Winfried Demary, Anke Liebhaber, Joachim Listing, Angela Zink, Anja Strangfeld
OBJECTIVE: To compare the 24-month course of health-related quality of life (HRQoL) in patients with long-standing RA treated with a conventional synthetic (cs) or a first, second or third biologic (b) DMARD in daily rheumatological care. METHODS: Patients enrolled in the German biologics register RABBIT who were observed over at least 12 months were stratified according to the nth bDMARD started at enrolment. HRQoL was captured by the SF36 health survey. Within strata of sequential bDMARD therapy, we examined patients' HRQoL at baseline and at follow-ups in comparison with the general population, the 24-month course of HRQoL of different bDMARDs and the proportion of patients exceeding the minimal detectable improvement of physical and mental health sum scores...
October 2015: Rheumatology
https://www.readbyqxmd.com/read/25991396/concomitant-methotrexate-and-tacrolimus-augment-the-clinical-response-to-abatacept-in-patients-with-rheumatoid-arthritis-with-a-prior-history-of-biological-dmard-use
#19
Nobunori Takahashi, Takayoshi Fujibayashi, Daihei Kida, Yuji Hirano, Takefumi Kato, Daizo Kato, Kiwamu Saito, Atsushi Kaneko, Yuichiro Yabe, Hideki Takagi, Takeshi Oguchi, Hiroyuki Miyake, Tsuyoshi Watanabe, Masatoshi Hayashi, Yasuhide Kanayama, Koji Funahashi, Masahiro Hanabayashi, Shinya Hirabara, Shuji Asai, Toki Takemoto, Kenya Terabe, Nobuyuki Asai, Yutaka Yoshioka, Naoki Ishiguro, Toshihisa Kojima
This observational retrospective study examined whether abatacept efficacy could be augmented with concomitant methotrexate (MTX) or tacrolimus (TAC) in patients with rheumatoid arthritis (RA) who experienced failure with prior biological disease-modifying antirheumatic drugs (DMARDs) and in whom favorable therapeutic efficacy is difficult to achieve. All patients with a prior biological DMARD history who were treated with abatacept for 52 weeks and registered in a Japanese multicentre registry were included...
October 2015: Rheumatology International
https://www.readbyqxmd.com/read/25805514/-how-do-register-data-support-clinical-decision-making
#20
A Strangfeld, A Richter
BACKGROUND: Patients in daily rheumatological care differ in their individual risk profiles from participants in randomized controlled trials (RCT), e.g. due to comorbidities and age. Transferring results from RCTs into routine daily practice is therefore limited. OBJECTIVE: The aim of this study was to evaluate the contribution of observational studies for decision-making in routine rheumatology practice. MATERIAL AND METHODS: We used data from the German biologics register RABBIT which includes patients with rheumatoid arthritis (RA) when starting synthetic (s) or biologic (b) disease-modifying antirheumatic drugs (DMARD)...
March 2015: Zeitschrift Für Rheumatologie
keyword
keyword
111811
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"